Prognostic and clinicopathological significance of Systemic Immune-Inflammation Index in cancer patients receiving immune checkpoint inhibitors: a meta-analysis

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135.
   PubMed Web of Science ®Google Scholar
• Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020;20(1):25–39.
   PubMed Web of Science ®Google Scholar
• Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10:727–742.
   PubMed Web of Science ®Google Scholar
• Twomey JD, Zhang BL. Cancer immunotherapy update: FDA-Approved checkpoint inhibitors and companion diagnostics. AAPS J. 2021;23:39.
   PubMed Web of Science ®Google Scholar
• Ren DX, Hua YZ, Yu BY, et al. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Mol Cancer. 2020;19(1):19.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer [Review]. Cell. 2010;140(6):883–899.
   PubMed Web of Science ®Google Scholar
• Bagley SJ, Kothari S, Aggarwal C, et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer. 2017;106:1–7.
   PubMed Web of Science ®Google Scholar
• Qi Y, Liao D, Fu X, et al. Elevated platelet-to-lymphocyte corresponds with poor outcome in patients with advanced cancer receiving anti-PD-1 therapy. Int Immunopharmacol. 2019;74:105707.
   PubMed Web of Science ®Google Scholar
• Brown JT, Liu Y, Shabto JM, et al. Baseline modified Glasgow prognostic score associated with survival in metastatic urothelial carcinoma treated with immune checkpoint inhibitors. Oncologist. 2021;26(5):397–405.
   PubMed Web of Science ®Google Scholar
• Bauckneht M, Genova C, Rossi G, et al. The role of the immune metabolic prognostic index in patients with non-small cell lung cancer (NSCLC) in radiological progression during treatment with nivolumab. Cancers. 2021;13(13):3117.
   Web of Science ®Google Scholar
• Wang S, Yang X, Yu Z, et al. The values of Systemic Immune-Inflammation Index and neutrophil-lymphocyte ratio in predicting testicular germ cell tumors: a retrospective clinical study. Front Oncol. 2022;12:893877.
   PubMed Web of Science ®Google Scholar
• Cao W, Shao Y, Zou S, et al. Prognostic significance of Systemic Immune-Inflammation Index in patients with bladder cancer: a systematic review and meta-analysis. Medicine. 2022;101(36):e30380.
   PubMed Web of Science ®Google Scholar
• Zhang B, Yao W. Prognostic role of the Systemic Immune-Inflammation Index in biliary tract cancers: a meta-analysis of 3,515 patients. World J Surg Oncol. 2022;20(1):320.
   PubMed Web of Science ®Google Scholar
• Chang L, Cheng Q, Ma Y, et al. Prognostic effect of the controlling nutritional status score in patients with esophageal cancer treated with immune checkpoint inhibitor. J Immunother. 2022:45(9):415–422.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang C, Peng Z, et al. Association of lymphocyte-to-monocyte ratio with survival in advanced gastric cancer patients treated with immune checkpoint inhibitor. Front Oncol. 2021;11:589022.
   PubMedGoogle Scholar
• De Giorgi U, Procopio G, Giannarelli D, et al. Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab. Clin Cancer Res. 2019;25(13):3839–3846.
   PubMed Web of Science ®Google Scholar
• Du F, Qiu Z, Ai W, et al. Blood tests predict the therapeutic prognosis of anti-PD-1 in advanced biliary tract cancer. J Leukoc Biol. 2021;110(2):327–334.
   PubMed Web of Science ®Google Scholar
• Ekinci F, Balcik OY, Demir B, et al. Systemic immune inflammation index as a key marker of survival and immune-related adverse events in immune checkpoint inhibitor therapy. J Coll Phys Surg Pak. 2022;32(8):996–1003.
   PubMed Web of Science ®Google Scholar
• Fornarini G, Rebuzzi SE, Banna GL, et al. Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort. ESMO Open. 2021;6(3):100118.
   PubMed Web of Science ®Google Scholar
• Huang R, Zheng Y, Zou W, et al. Blood biomarkers predict survival outcomes in patients with hepatitis B Virus-Induced hepatocellular carcinoma treated with PD-1 inhibitors. J Immunol Res. 2022;2022:3781109.
   PubMed Web of Science ®Google Scholar
• Iinuma K, Enomoto T, Kawada K, et al. Utility of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune inflammation index as prognostic, predictive biomarkers in patients with metastatic renal cell carcinoma treated with nivolumab and ipilimumab. JCM. 2021;10(22):5325.
   Google Scholar
• Kauffmann-Guerrero D, Kahnert K, Kiefl R, et al. Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study. Sci Rep. 2021;11(1):10919.
   PubMed Web of Science ®Google Scholar
• Lee JH, Hyung S, Lee J, et al. Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study. J Immunother Cancer. 2022;10(8):e005226.
   PubMed Web of Science ®Google Scholar
• Liu J, Li S, Zhang S, et al. Systemic Immune-Inflammation Index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. J Clin Lab Anal. 2019;33(8):e22964.
   PubMed Web of Science ®Google Scholar
• Qu Z, Wang Q, Wang H, et al. The effect of inflammatory markers on the survival of advanced gastric cancer patients who underwent anti-programmed death 1 therapy. Front Oncol. 2022;12:783197.
   PubMed Web of Science ®Google Scholar
• Shang J, Han X, Zha H, et al. Systemic Immune-Inflammation Index and changes of neutrophil-lymphocyte ratio as prognostic biomarkers for patients with pancreatic cancer treated with immune checkpoint blockade. Front Oncol. 2021;11:585271.
   PubMed Web of Science ®Google Scholar
• Stühler V, Herrmann L, Rausch S, et al. Role of the Systemic Immune-Inflammation Index in patients with metastatic renal cell carcinoma treated with first-line ipilimumab plus nivolumab. Cancers. 2022;14(12):2972.
   PubMed Web of Science ®Google Scholar
• Wu X, Han R, Zhong Y, et al. Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma. Cancer Cell Int. 2021;21(1):356.
   PubMed Web of Science ®Google Scholar
• Xiong Q, Huang Z, Xin L, et al. Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1/PD-L1 antibody in SCLC patients at early phase. Cancer Immunol Immunother. 2021;70(3):713–720.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269, W64.
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605.
   PubMed Web of Science ®Google Scholar
• Shaul ME, Fridlender ZG. Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol. 2019;16(10):601–620.
   PubMed Web of Science ®Google Scholar
• Jaillon S, Ponzetta A, Di Mitri D, et al. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020;20(9):485–503.
   PubMed Web of Science ®Google Scholar
• Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9(2):237–249.
   PubMed Web of Science ®Google Scholar
• Palacios-Acedo AL, Mège D, Crescence L, et al. Platelets, thrombo-inflammation, and cancer: collaborating with the enemy. Front Immunol. 2019;10:1805.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang Z, Hu Y, et al. Pretreatment neutrophil-to-lymphocyte ratio (NLR) may predict the outcomes of advanced non-small-cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs). Front Oncol. 2020;10:654.
   PubMed Web of Science ®Google Scholar
• Yang J, Liao D, Chen C, et al. Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/sox-2 signaling pathway. Stem Cells. 2013;31(2):248–258.
   PubMed Web of Science ®Google Scholar
• Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398(10304):1002–1014.
   PubMed Web of Science ®Google Scholar
• Kono K, Nakajima S, Mimura K. Current status of immune checkpoint inhibitors for gastric cancer. Gastric Cancer. 2020;23(4):565–578.
   PubMed Web of Science ®Google Scholar
• Onoi K, Chihara Y, Uchino J, et al. Immune checkpoint inhibitors for lung cancer treatment: a review. J Clin Med. 2020;9:1362.
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran A, Cimadamore A, Blanca A, et al. Immune checkpoint inhibitors for the treatment of bladder cancer. Cancers. 2021;13:131.
   PubMedGoogle Scholar
• Zhou Y, Dai M, Zhang Z. Prognostic significance of the Systemic Immune-Inflammation Index (SII) in patients with small cell lung cancer: a meta-analysis. Front Oncol. 2022;12:814727.
   PubMed Web of Science ®Google Scholar
• Li X, Zhang S, Lu J, et al. The prognostic value of Systemic Immune-Inflammation Index in surgical esophageal cancer patients: an updated meta-analysis. Front Surg. 2022;9:922595.
   PubMed Web of Science ®Google Scholar
• Li J, Cao D, Huang Y, et al. The prognostic and clinicopathological significance of Systemic Immune-Inflammation Index in bladder cancer. Front Immunol. 2022;13:865643.
   PubMed Web of Science ®Google Scholar
• Li M, Li Z, Wang Z, et al. Prognostic value of Systemic Immune-Inflammation Index in patients with pancreatic cancer: a meta-analysis. Clin Exp Med. 2022:22:637–646.
   PubMed Web of Science ®Google Scholar
• Dong M, Shi Y, Yang J, et al. Prognostic and clinicopathological significance of Systemic Immune-Inflammation Index in colorectal cancer: a meta-analysis. Ther Adv Med Oncol. 2020;12:1758835920937425.
   Web of Science ®Google Scholar
• Shui Y, Li M, Su J, et al. Prognostic and clinicopathological significance of Systemic Immune-Inflammation Index in pancreatic cancer: a meta-analysis of 2,365 patients. Aging. 2021;13(16):20585–20597.
   PubMedGoogle Scholar